Business Wire

Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract

2.8.2021 09:00:00 EEST | Business Wire | Press release

Share

Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America.

Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospitals. This programme will ensure the right medicines are in the right place at the right time and will undoubtedly improve care for our patients.”

Giorgio Pavesi, Managing Director of Deenova in Italy stated: “I am extremely proud of the teamwork and dedication exhibited by our employees and those of University Hospitals of Leicester NHS Trust, proving to the health care industry the patient safety and economic advantages of Deenova´s unique Closed-Loop Medication Unit Dose management system and services, as evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation of Deenova solutions. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economical benefits, leading to this award.”

Deenova plans to fulfill University Hospitals of Leicester NHS Trust’s contract award with delivery, installation and full service/support for 3 All-in-1 and 1 Acced Packaging Robots, 56 All-in-1 Station Medication Dispensing Robots, and more than 100 All-in-1 Trolleys with secure bed-side verification.

East Midlands AHSN Commercial Director, Tim Robinson, said: “A key role of AHSNs is to help build collaboration across sectors, and in particular to connect commercial innovators with the heath and care organisations that could benefit from their innovations. With this in mind, we welcome the progress made in Leicester - this is a great example of how the NHS and commercial sector can work in partnership. As well as the potential to benefit patients and generate efficiencies, we also welcome the investment into the East Midlands and the jobs this partnership will create.”

Information

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and making the best use of staff time. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

University Hospitals of Leicester NHS Trust : Every day at Leicester’s Hospitals we save lives, improve lives and usher in new life. We want to continue to improve everything that we do, so that we can achieve our vision: Caring at its best for every patient, every time. As one of the largest NHS Trusts in the country, our contribution goes beyond health; we are the largest employer in our region, we educate and train the staff of the future, push the boundaries of research and with our £1bn turnover are an economic engine for East Midlands and beyond. This is a particularly exciting time for Leicester’s Hospitals. We have been given £450m to reconfigure services and build new hospitals. This will include a new Children’s Hospital, Maternity Hospital, Treatment Centre and two new Intensive Care Units. For more information please visit: www.leicestershospitals.nhs.uk

The East Midlands Academic Health Science Network (EMAHSN) is one of 15 Academic Health Science Networks in England that operate as the innovation arm of the NHS. AHSNs bring together the NHS, universities, industry and social care to transform health and stimulate economic growth. In the East Midlands our current priorities focus on identifying and spreading innovations that respond to the COVID-19 pandemic and the recovery of services, along with priority themes including mental health, patient safety and optimising medicines. For more information please visit: www.emahsn.org.uk

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts at Deenova:
Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 16:30:00 EEST | Press release

Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country. The funding will advance Project Obsidian, the world's first commercial superhot geothermal power plant, in Central Oregon. It will support analysis of the drilling, stimulation, and flow results of the first two wells to optimize a third well at the Obsidian site. The three-well configuration is targeting average reservoir temperatures of over 300°C and is designed to demonstrate more than 25 megawatts of gross electric power capacity. The DOE funding will also enable Qu

From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 16:00:00 EEST | Press release

Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and their families access care, adopt healthier habits, and improve long-term oral health outcomes. “At Colgate-Palmolive, we believe oral health and healthier, brighter futures are inextricably link

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio22.9.2026 15:30:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 - October 3, 2026, in Vienna, Austria. "The breadth of research being presented at EADV 2026 highlights the strength of our Inflammation and Autoimmunity portfolio," said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Data presentations in hidradenitis suppurativa, atopic dermatitis and prurigo nodularis demonstrate our commitment to advancing innovation across immune-mediated skin diseases and deepening our understanding of the patient experience." Details on key Incyte data presentations at EADV include: Oral Presentations Atopic Dermatitis Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL) (Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:0

Citi Wealth’s 2026 Global Family Office Report Reveals Clients Are Shifting Their Focus Towards Public Equities While Becoming More Deliberate and Resilient Amid Uncertainty22.9.2026 15:30:00 EEST | Press release

Citi Wealth today released its 2026 Global Family Office Report, offering an inside perspective into the thinking and behaviors of the world’s most sophisticated investors. The report was compiled by Citi Wealth’s Global Family Office Group, which works with more than 1,900 family offices worldwide. Conducted in June and July 2026, the survey sheds light on how over 350 family offices in more than 40 countries are navigating new complexities in an era defined by uncertainty. Today’s leading family offices are building long-term strategies underpinned by three key themes: capital, capability and continuity. They are investing with confidence -- becoming more institutional in how they invest, more sophisticated in how they manage risk, and more intentional in how they prepare for the future. Families also are prioritizing leadership succession and generational transition with new urgency. Key takeaways include: Strong Performance in the Face of Rising Uncertainty: Despite shifting macroe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye